Previous 10 | Next 10 |
home / stock / bayzf / bayzf news
Bayer (BAYZF) becomes the latest European pharma giant to ramp up global vaccine production after agreeing to produce the COVID-19 vaccine from CureVac N.V. ([[CVAC]] +8.1%), which is currently undergoing a pivotal Phase 2b/3 trial globally.Expecting to launch the production in...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Many assets that fell to generational lows earlier in the...
2020 was a busy year for global healthcare with unprecedented efforts to develop vaccines, treatments, and diagnostics for COVID-19. Deal flow in the sector continued to gain momentum in 2020, with M&A transactions and product licensing deals totalling five-year highs as large-cap...
Many stocks are in a bubble and extremely overvalued. While it seems easy to decide in which stocks not to invest, it is much more difficult to find good picks in this market driven by irrational exuberance. Finding recession-proof companies is a good starting point, but the stock...
The time has come for us to look at just what sort of companies may be appealing to invest in during January of 2021. We look at the areas of Financials, Real Estate, Industrials, IT and Pharma/Healthcare. The ongoing records in the market has caused many of our previously-apparen...
Stocks finished the year strongly with cyclicals and energy stocks rallying strongly. I am continuing my monthly investment plans and suspiciously follow the massive rally in technology stocks as well as the vaccine-driven rebound in value stocks. My dividend income amounted to $3...
The potential new blockbuster drugs of Bayer (BAYZF) will not be able to offset a fall in revenues when its two best-sellers go off patent, says Stefan Oelrich, the pharma head of the company as quoted by the Financial Times.Quick look at the company's latest pharma quarterly results which in...
The FDA, under priority review, has accepted Bayer's (BAYZF) marketing application seeking approval for finerenone, for chronic kidney disease and type 2 diabetes.The submission is based on positive results from Phase 3 study that demonstrated that finerenone delayed the progression of C...
This article initiates coverage of Siemens Aktiengesellschaft often called Siemens. Siemens is a leading player in its industry and is a diversified defensive way to gain exposure to global infrastructure stimulus measures. The share price has risen 16% over the past year and as s...
The FDA has approved Bayer's ([[BAYZF]] -2.3%) supplemental marketing application allowing to add overall survival ((OS)) and other secondary endpoint data from Phase 3 ARAMIS trial to the prescribing information for its cancer treatment Nubeqa (darolutamide).In the trial, Nubeqa si...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG Registered Shares Company Name:
BAYZF Stock Symbol:
OTCMKTS Market:
NORTHAMPTON, MA / ACCESSWIRE / August 29, 2023 / Bayer - As climate change quickens, societal expectations increase and the threat of resistance grows, new crop protection solutions are imperative. Advances in the life sciences and data-driven technologies hold the key to expanding our pipeline ...
Monsanto Must Face Georgia State Jurors in Lawsuit Over Cancer-Causing Roundup Herbicide PR Newswire 11th Circuit opinion finds chemical giant subject to state's warning label laws Nachawati Law Group trial lawyers gearing up for next Roundup cancer trial in Au...
Bayer Runs Out of Appeals at US Supreme Court as Thousands of Cancer Lawsuits Await over Roundup Herbicide PR Newswire Fears Nachawati trial lawyers gearing up for next Roundup cancer trial in August WASHINGTON , June 22, 2022 /PRNewswire/ -- Baye...